The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Can Miravirsen Stop HCV with Little Side Effects?

Back to News Homepage

Next

Dental Practice Possibly Exposes 7,000 Patients to Hepatitis and HIV

Phase 3 Trial of ION-1 Will Continue

March 28, 2013

Print this page

Learn more about the phase 3 trial by Gilead Sciences Inc., which is evaluating once-daily fixed-dose combination of the nucleotide sofosbuvir and the NS5A inhibitor ledipasvir.

Gilead To Continue Phase 3 Trial Of Hepatitis C Compound Without Change

By RTT News,  March 26, 2013

RTTNews.com) – Biopharmaceutical company Gilead Sciences Inc. ( GILD ) Tuesday said the phase 3 trial ION-1, evaluating once-daily fixed-dose combination of the nucleotide sofosbuvir and the NS5A inhibitor ledipasvir with and without ribavirin for 12 or 24 weeks among treatment-naïve genotype 1 patients with hepatitis C virus infection should continue without any modification.

Continue reading this entire article:
http://www.nasdaq.com/article/gilead-to-continue-phase-3-trial-of-hepatitis-c-compound-without-change-20130326-00437#.UVRCBUczJhp

1 Comment
Share
Share

Previous

Can Miravirsen Stop HCV with Little Side Effects?

Back to News Homepage

Next

Dental Practice Possibly Exposes 7,000 Patients to Hepatitis and HIV

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.